Pyxis Oncology (PYXS) Interest Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Interest Expenses data on file, last reported at -$2.4 million in Q4 2025.

• On a quarterly basis, Interest Expenses fell 369.16% year-over-year to -$2.4 million in Q4 2025; TTM through Dec 2025 was $86000.0, a 105.97% increase from a year earlier, with the FY2025 full-year figure at $25.8 million, down 81.63% from the prior year.
• Interest Expenses for Q4 2025 stood at -$2.4 million, down from $6.2 million in the prior quarter.
• Over the last five years, Interest Expenses for PYXS reached as high as $34.8 million in Q3 2021 and fell as low as -$2.4 million in Q4 2025.
• Historically, Interest Expenses has averaged $5.9 million across 5 years, with a median of $2.5 million in 2023.
• Across the five-year window, Interest Expenses jumped 4560.18% in 2024 and sank 369.16% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $16.4 million in 2021, then sank by 103.88% to -$637000.0 in 2022, then tumbled by 166.72% to -$1.7 million in 2023, then soared by 152.68% to $895000.0 in 2024, then sank by 369.16% to -$2.4 million in 2025.
• Per Business Quant data, the three most recent Interest Expenses figures were -$2.4 million in Q4 2025, $6.2 million in Q3 2025, and $800000.0 in Q2 2025.